258 related articles for article (PubMed ID: 19838701)
1. Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-Z EGFR:2377 Affibody molecule: aspect of the injected tracer amount.
Tolmachev V; Rosik D; Wållberg H; Sjöberg A; Sandström M; Hansson M; Wennborg A; Orlova A
Eur J Nucl Med Mol Imaging; 2010 Mar; 37(3):613-22. PubMed ID: 19838701
[TBL] [Abstract][Full Text] [Related]
2. Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts.
Malmberg J; Perols A; Varasteh Z; Altai M; Braun A; Sandström M; Garske U; Tolmachev V; Orlova A; Karlström AE
Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):481-92. PubMed ID: 22322933
[TBL] [Abstract][Full Text] [Related]
3. Influence of an aliphatic linker between DOTA and synthetic Z(HER2:342) Affibody molecule on targeting properties of the (111)In-labeled conjugate.
Tolmachev V; Feldwisch J; Lindborg M; Baastrup B; Sandström M; Orlova A
Nucl Med Biol; 2011 Jul; 38(5):697-706. PubMed ID: 21718945
[TBL] [Abstract][Full Text] [Related]
4. Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules.
Perols A; Honarvar H; Strand J; Selvaraju R; Orlova A; Karlström AE; Tolmachev V
Bioconjug Chem; 2012 Aug; 23(8):1661-70. PubMed ID: 22768790
[TBL] [Abstract][Full Text] [Related]
5. Preclinical evaluation of anti-HER2 Affibody molecules site-specifically labeled with 111In using a maleimido derivative of NODAGA.
Altai M; Perols A; Karlström AE; Sandström M; Boschetti F; Orlova A; Tolmachev V
Nucl Med Biol; 2012 May; 39(4):518-29. PubMed ID: 22172396
[TBL] [Abstract][Full Text] [Related]
6. The use of radiocobalt as a label improves imaging of EGFR using DOTA-conjugated Affibody molecule.
Garousi J; Andersson KG; Dam JH; Olsen BB; Mitran B; Orlova A; Buijs J; Ståhl S; Löfblom J; Thisgaard H; Tolmachev V
Sci Rep; 2017 Jul; 7(1):5961. PubMed ID: 28729680
[TBL] [Abstract][Full Text] [Related]
7. Imaging of insulinlike growth factor type 1 receptor in prostate cancer xenografts using the affibody molecule 111In-DOTA-ZIGF1R:4551.
Tolmachev V; Malmberg J; Hofström C; Abrahmsén L; Bergman T; Sjöberg A; Sandström M; Gräslund T; Orlova A
J Nucl Med; 2012 Jan; 53(1):90-7. PubMed ID: 22173843
[TBL] [Abstract][Full Text] [Related]
8. Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels.
Tolmachev V; Wållberg H; Sandström M; Hansson M; Wennborg A; Orlova A
Eur J Nucl Med Mol Imaging; 2011 Mar; 38(3):531-9. PubMed ID: 21069318
[TBL] [Abstract][Full Text] [Related]
9. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.
Orlova A; Jonsson A; Rosik D; Lundqvist H; Lindborg M; Abrahmsen L; Ekblad C; Frejd FY; Tolmachev V
J Nucl Med; 2013 Jun; 54(6):961-8. PubMed ID: 23528382
[TBL] [Abstract][Full Text] [Related]
10. Imaging of platelet-derived growth factor receptor β expression in glioblastoma xenografts using affibody molecule 111In-DOTA-Z09591.
Tolmachev V; Varasteh Z; Honarvar H; Hosseinimehr SJ; Eriksson O; Jonasson P; Frejd FY; Abrahmsen L; Orlova A
J Nucl Med; 2014 Feb; 55(2):294-300. PubMed ID: 24408895
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules.
Ahlgren S; Orlova A; Rosik D; Sandström M; Sjöberg A; Baastrup B; Widmark O; Fant G; Feldwisch J; Tolmachev V
Bioconjug Chem; 2008 Jan; 19(1):235-43. PubMed ID: 18163536
[TBL] [Abstract][Full Text] [Related]
12. Influence of nuclides and chelators on imaging using affibody molecules: comparative evaluation of recombinant affibody molecules site-specifically labeled with ⁶⁸Ga and ¹¹¹In via maleimido derivatives of DOTA and NODAGA.
Altai M; Strand J; Rosik D; Selvaraju RK; Eriksson Karlström A; Orlova A; Tolmachev V
Bioconjug Chem; 2013 Jun; 24(6):1102-9. PubMed ID: 23705574
[TBL] [Abstract][Full Text] [Related]
13. 68Ga-DOTA-affibody molecule for in vivo assessment of HER2/neu expression with PET.
Kramer-Marek G; Shenoy N; Seidel J; Griffiths GL; Choyke P; Capala J
Eur J Nucl Med Mol Imaging; 2011 Nov; 38(11):1967-76. PubMed ID: 21748382
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the first
Honarvar H; Müller C; Cohrs S; Haller S; Westerlund K; Karlström AE; van der Meulen NP; Schibli R; Tolmachev V
Nucl Med Biol; 2017 Feb; 45():15-21. PubMed ID: 27837664
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of a maleimido derivative of CHX-A'' DTPA for site-specific labeling of affibody molecules.
Tolmachev V; Xu H; Wållberg H; Ahlgren S; Hjertman M; Sjöberg A; Sandström M; Abrahmsén L; Brechbiel MW; Orlova A
Bioconjug Chem; 2008 Aug; 19(8):1579-87. PubMed ID: 18620447
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of backbone-cyclized HER2-binding 2-helix affibody molecule for in vivo molecular imaging.
Honarvar H; Jokilaakso N; Andersson K; Malmberg J; Rosik D; Orlova A; Karlström AE; Tolmachev V; Järver P
Nucl Med Biol; 2013 Apr; 40(3):378-86. PubMed ID: 23357083
[TBL] [Abstract][Full Text] [Related]
17. Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.
Ahlgren S; Wållberg H; Tran TA; Widström C; Hjertman M; Abrahmsén L; Berndorff D; Dinkelborg LM; Cyr JE; Feldwisch J; Orlova A; Tolmachev V
J Nucl Med; 2009 May; 50(5):781-9. PubMed ID: 19372467
[TBL] [Abstract][Full Text] [Related]
18. Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties.
Wållberg H; Orlova A; Altai M; Hosseinimehr SJ; Widström C; Malmberg J; Ståhl S; Tolmachev V
J Nucl Med; 2011 Mar; 52(3):461-9. PubMed ID: 21321280
[TBL] [Abstract][Full Text] [Related]
19. [99mTc(CO)3]+-(HE)3-ZIGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours.
Orlova A; Hofström C; Strand J; Varasteh Z; Sandstrom M; Andersson K; Tolmachev V; Gräslund T
Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):439-49. PubMed ID: 23179942
[TBL] [Abstract][Full Text] [Related]
20. Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry.
Tolmachev V; Friedman M; Sandström M; Eriksson TL; Rosik D; Hodik M; Ståhl S; Frejd FY; Orlova A
J Nucl Med; 2009 Feb; 50(2):274-83. PubMed ID: 19164241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
